NPM1 and acute myeloid leukemia: Conversely, the 2022 recommendations classified all FLT3-ITD patients lacking favorable cytogenetics or adverse genetic lesions in the intermediate risk group, given the challenges posed by the standardization of the assay measuring AR, the evidence of a beneficial impact of midostaurin-based regimens in FLT3-ITD AML irrespective of AR and NPM1 mutational status, and the increased role of MRD [39,156].